167 related articles for article (PubMed ID: 1760815)
1. Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.
Liberati AM; Horisberger M; Schippa M; Di Clemente F; Fizzotti M; Filippo S; Proietti MG; Arzano S; Berruto P; Palmisano L
Cancer Immunol Immunother; 1991; 34(2):115-22. PubMed ID: 1760815
[TBL] [Abstract][Full Text] [Related]
2. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
[TBL] [Abstract][Full Text] [Related]
3. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.
Fierlbeck G; Schreiner T; Rassner G
Cancer Immunol Immunother; 1995 Mar; 40(3):157-64. PubMed ID: 7728774
[TBL] [Abstract][Full Text] [Related]
4. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
5. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
8. Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.
Rosenblum MG; Riso A; Gutterman JU
Cancer Chemother Pharmacol; 1986; 16(3):273-6. PubMed ID: 3084109
[TBL] [Abstract][Full Text] [Related]
9. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
10. Induction of intracellular and plasma 2',5'-oligoadenylate synthetase by pentostatin.
Ho AD; Klotzbücher A; Gross A; Dietz G; Mestan J; Jakobsen H; Hunstein W
Leukemia; 1992 Mar; 6(3):209-14. PubMed ID: 1564958
[TBL] [Abstract][Full Text] [Related]
11. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
[TBL] [Abstract][Full Text] [Related]
12. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
[TBL] [Abstract][Full Text] [Related]
13. Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients.
Liberati AM; De Angelis V; Fizzotti M; Schippa M; Cecchini M; Adiuto D; Di Clemente F; Palmisano L; Micozzi E; Zuccaccia M
Cancer Immunol Immunother; 1994 May; 38(5):323-31. PubMed ID: 7512888
[TBL] [Abstract][Full Text] [Related]
14. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro induction of (2'-5') oligoadenylate synthetase by human interferons in leukocytes from healthy donors and patients with renal cancer and hairy cell leukemia.
Ferbus D; Billard C; Sigaux F; Thang MN; Falcoff E
J Biol Regul Homeost Agents; 1987; 1(3):147-53. PubMed ID: 2459906
[TBL] [Abstract][Full Text] [Related]
16. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
[TBL] [Abstract][Full Text] [Related]
17. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.
Fierlbeck G; Schreiner T; Schaber B; Walser A; Rassner G
Cancer Immunol Immunother; 1994 Oct; 39(4):263-8. PubMed ID: 7954528
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
20. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta.
Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F
J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
